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Background. Hundreds of studies have evaluated the diagnostic accuracy of nucleic-acid amplification tests (NAATs) for
tuberculosis (TB). Commercial tests have been shown to give more consistent results than in-house assays. Previous meta-
analyses have found high specificity but low and highly variable estimates of sensitivity. However, reasons for variability in
study results have not been adequately explored. We performed a meta-analysis on the accuracy of commercial NAATs to
diagnose pulmonary TB and meta-regression to identify factors that are associated with higher accuracy. Methodology/
Principal Findings. We identified 2948 citations from searching the literature. We found 402 articles that met our eligibility
criteria. In the final analysis, 125 separate studies from 105 articles that reported NAAT results from respiratory specimens were
included. The pooled sensitivity was 0.85 (range 0.36–1.00) and the pooled specificity was 0.97 (range 0.54–1.00). However,
both measures were significantly heterogeneous (p,.001). We performed subgroup and meta-regression analyses to identify
sources of heterogeneity. Even after stratifying by type of commercial test, we could not account for the variability. In the
meta-regression, the threshold effect was significant (p=.01) and the use of other respiratory specimens besides sputum was
associated with higher accuracy. Conclusions/Significance. The sensitivity and specificity estimates for commercial NAATs in
respiratory specimens were highly variable, with sensitivity lower and more inconsistent than specificity. Thus, summary
measures of diagnostic accuracy are not clinically meaningful. The use of different cut-off values and the use of specimens
other than sputum could explain some of the observed heterogeneity. Based on these observations, commercial NAATs alone
cannot be recommended to replace conventional tests for diagnosing pulmonary TB. Improvements in diagnostic accuracy,
particularly sensitivity, need to be made in order for this expensive technology to be worthwhile and beneficial in low-resource
countries.
Citation: Ling DI, Flores LL, Riley LW, Pai M (2008) Commercial Nucleic-Acid Amplification Tests for Diagnosis of Pulmonary Tuberculosis in
Respiratory Specimens: Meta-Analysis and Meta-Regression. PLoS ONE 3(2): e1536. doi:10.1371/journal.pone.0001536
INTRODUCTION
Tuberculosis (TB) is a major global health problem. Each year, 8
to 9 million people develop disease, and 2 million die [1].
Pulmonary TB is the most common form of the disease [2].
Diagnosis of TB relies on the detection of acid-fast bacilli by
microscopy (smear) and culture. Microscopy is rapid, specific, and
inexpensive but has low sensitivity [3,4]. Culture is more sensitive,
but results can take several weeks. In addition, culture may be
falsely-negative in 10–20% of cases [5]. Better efforts to control TB
require faster and more accurate diagnostic tests [6–8]. Nucleic
acid amplification tests (NAATs), which can give results in 3–
6 hours, have been developed to address these issues [9].
The polymerase chain reaction (PCR) is the most common
NAAT. Tests include those that are ‘‘in-house’’, when they are
based on a protocol developed in a non-commercial laboratory
(‘‘home-brew’’), or commercial kits. Several commercial NAATs
exist, and each uses a different method to amplify specific nucleic-
acid regions in the Mycobacterium tuberculosis complex. These kits
include: the GenProbe Amplified M. tuberculosis Direct test
(AMTD), the Roche Amplicor MTB test, the Cobas Amplicor
test, the Abbott LCx test, and the BD-ProbeTec (SDA) test.
Another NAAT has been recently developed—the Loop-mediated
Isothermal Amplification (LAMP) test, but research experience is
limited with this test [10]. Table 1 provides a summary of the
different commercial tests. The LCx kit is no longer in use, and
Becton Dickinson has produced an enhanced version of the SDA
test (BD-ProbeTec-ET). The Food and Drug Administration
(FDA) has approved the use of select commercial NAATs for only
respiratory specimens. In addition, the AMTD and Amplicor tests
are licensed for testing smear-positive specimens, while the FDA
recently approved a 2
nd-generation AMTD (E-AMTD) test for
smear-negative specimens [11]. The LCx, BD-ProbeTec-ET, and
LAMP tests are currently not FDA-approved.
Systematic reviews of previous studies have suggested that the
diagnostic accuracy of NAATs varies more among in-house
NAATs than commercial tests [12,13]. A meta-analysis on the use
of in-house PCR assays for testing sputum samples found
significant heterogeneity and could not summarize the measures
of diagnostic accuracy (i.e. sensitivity and specificity) [14]. Several
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in both pulmonary and extrapulmonary TB [12,13,15–17]. Most
of them have reported high and consistent specificity but low and
inconsistent estimates of sensitivity [12,13,15]. Smear-negative
patients may be the most likely group to benefit from the use of
NAATs. If the NAAT result is positive, a faster diagnosis can lead
to an earlier initiation of therapy [11]. However, studies have
shown that sensitivity is lower for smear-negative TB compared to
smear-positive TB [12,13,15,18]. One meta-analysis on the use of
commercial NAATs for only smear-negative patients found that
the sensitivity estimates were too low and variable to be used for
confirming diagnosis in this group [16]. Another recent meta-
analysis evaluated diagnostic accuracy for pulmonary TB stratified
by smear status [18]. It concluded that the low sensitivity of smear-
negative patients precludes the use of commercial NAATs for
ruling out TB. Its high specificity in this group of patients,
however, is useful for ruling in TB. The same study also noted that
the high sensitivity in smear-positive samples could be helpful in
ruling out a diagnosis of pulmonary TB due to infection by non-
tuberculous mycobacteria (NTM) [18]. In our meta-analysis, we
used a comprehensive search strategy to determine the accuracy of
commercial NAATs for diagnosing pulmonary TB in combined
smear-positive and smear-negative respiratory specimens. We
further explore factors that may be accountable for differences
among studies by meta-regression analysis.
METHODS
Search strategy
We systematically searched the literature using predetermined
inclusion criteria [19]. Criteria included: use of commercial
NAATs on respiratory specimens for diagnosing pulmonary TB,
comparison of NAAT result with culture as reference standard,
information to calculate sensitivity and specificity, and minimum
sample size of 50 to avoid selection bias [20]. We searched
PUBMED (1985–2006), EMBASE (1988–2002), Web of Science
(1990–2002), BIOSIS (1993–2002), Cochrane Library (2002; Issue
2), and LILACS (1990–2002). In addition, we reviewed the
reference lists of several previously published reviews on NAATs
[12–16,18]. Further, we hand-searched the Journal of Clinical
Microbiology, a high-yield journal for this review topic. Search terms
included ‘‘tuberculosis, mycobacterium tuberculosis, nucleic acid
amplification techniques, direct amplification test, polymerase
chain reaction, ligase chain reaction, Amplicor, Cobas, Roche,
Gen-Probe, Abbott, BD-ProbeTec, molecular diagnostic tech-
niques, sensitivity and specificity, accuracy, and predictive value’’.
Reference lists from included studies were also searched. In
addition, experts and commercial NAAT manufacturers were
contacted for additional studies. This search criteria has been
reported in previous meta-analyses [12–14].
Study selection
We identified 2948 citations from the initial search. After
screening titles and abstracts, 471 English and Spanish articles
were eligible for full-text review. Of these, 69 articles were
excluded, and 402 articles on the use of commercial NAATs for all
forms of TB were included (screening done by two reviewers). A
total of 142 articles focused on respiratory specimens [sputa,
bronchial aspirates, bronchoalveolar lavages (BAL), and tracheal
aspirates] for the diagnosis of pulmonary TB. Some articles
considered gastric aspirates as respiratory specimens. They were
accepted if the number of gastric aspirates was less than 5% of the
total sample size. A total of 37 articles were further excluded from
data extraction, and 105 articles were included in our meta-
analysis [21–125]. Several articles compared more than one
NAAT against the same reference standard in head-to-head trials,
in which case each comparison was considered as a separate study.
Thus, the total number of studies in the final analysis was 125.
Figure 1 displays how the studies were selected.
Data extraction
We created and piloted a data extraction form with a subset of
eligible studies. Based upon experience gained in the pilot study,
the data extraction form was finalized. The final set of studies was
assessed with the standardized form by two reviewers (DIL and
LLF), and any differences were resolved by consensus. Many
articles compared NAAT results to more than one reference
standard, and we used a hierarchical approach to choose one
comparison from each study: (1) culture result plus clinical data
(most preferred reference standard) (2) culture result alone and (3)
clinical data alone (least preferred reference standard). We used
the specimen as the unit of analysis when possible. We also chose
to use data that were not subject to discrepant analyses (i.e.
unresolved data) when available, since resolved data after
discrepant analyses are a potential source of bias and result in
higher estimates of accuracy [126]. In addition, NTM and
inhibited specimens were excluded if possible.
Assessment of study quality
We assessed the quality of studies using the following criteria,
suggested as important for diagnostic studies [127]: (1) Was there a
comparison of the commercial NAAT with an independent,
appropriate reference standard? (2) Was the NAAT result
interpreted without knowledge of the results of the reference
standard (blinded interpretation) and vice-versa? (3) Did the whole
sample or a randomly selected subset of the sample receive
verification using the reference standard? and (4) Did the study
prospectively recruit consecutive patients suspected of having
pulmonary tuberculosis (i.e. cross-sectional vs case-control design)?
Table 1. Summary of Commercial Nucleic-Acid Amplification Tests (NAAT) for TB
..................................................................................................................................................
NAAT Manufacturer Method
Amplified M. tuberculosis Direct Test (AMTD) Gen-Probe Inc. San Diego, CA Transcription-mediated amplification of rRNA
Amplicor MTB Roche Molecular Systems Branchburg, NJ PCR amplification of 16s rRNA
Cobas Amplicor Roche Diagnostic Systems Mannheim, GERMANY PCR amplification of 16s rRNA
LCx (discontinued) Abbott Laboratories Abbott Park, IL Ligase chain reaction amplication of 38kDa protein
BD-ProbeTec Direct (SDA) Becton Dickinson Diagnostic Systems Sparks, MD Strand displacement amplification of IS6110 and 16s rRNA
Loop-mediated Isothermal Amplification (LAMP) Eiken Chemical Co. Ltd. Tokyo, JAPAN Isothermal amplification and visual readout with UV
fluorescence
doi:10.1371/journal.pone.0001536.t001
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Data were analyzed using Meta-Disc (version 1.4) software [128].
We pooled the data with the DerSimonian-Laird random effects
model (REM) [20,129–131]. The REM gives more conservative
estimates with wider confidence intervals because it assumes that
the meta-analysis includes only a sample of all possible studies
[19,132,133]. In addition, the REM accounts for both within-
study variability (random error) and between-study variability
(heterogeneity). Accuracy measures include: sensitivity, specificity,
positive likelihood ratio (LR+), negative likelihood ratio (LR-), and
the diagnostic odds ratio (DOR). Sensitivity is the proportion of
positive test results among those with the target disease. Specificity is
the proportion of negative test results among those without the
disease. In a clinical setting, likelihood ratios are considered useful.
The LR+ measures how much more frequent a positive test is found
in diseased versus non-diseased individuals. On the other hand, the
LR- measures how more likely a negative result is found in diseased
versus non-diseased individuals. The DOR, or the odds of a positive
resultindiseasedindividualscomparedtotheoddsofapositiveresult
in non-diseased individuals, combines both likelihood ratios and is a
global measure of test performance [134]. A value of 1 would
indicate that the test cannot discriminate between people with and
without disease. The DOR is calculated by LR+/LR2 or [sensitivity/
(1-specificity)]/[(1-sensitivity)/specificity] [134].
Each study in the meta-analysis contributed a pair of numbers:
sensitivity and specificity. Since these measures tend to be strongly
correlated and vary with the thresholds (cut-off values for
determining test positives) used across the individual studies, it is
standard practice to analyze sensitivity and specificity proportions
as pairs, and to also explore the effect of the threshold on study
results. To do this, we performed the summary receiver operating
characteristic (SROC) curve analysis [131,135]. The SROC
displays each study’s sensitivity and specificity estimates within
the ROC space. A regression curve is fitted through the
distribution of pairs of sensitivity and specificity. A shoulder-like
curve indicates that the variability between studies may be due to
the threshold effect (i.e. variation in cut-off values used across
studies) and that an underlying common DOR exists that does not
change with the threshold [130,135,136]. A non shoulder-like
curve shows that sensitivity and specificity are not correlated. The
area under the regression curve also measures the overall accuracy
of diagnostic tests. If the area under the curve (AUC) is 100%, then
the test differentiates perfectly between diseased and non-diseased
individuals. An AUC of 50% indicates poor diagnostic accuracy
[130,135,136].
Meta-regression
Heterogeneity in meta-analysis refers to a high degree of
variability in study results (e.g. variability in sensitivity estimates).
Such heterogeneity could be due to variability in thresholds (cut-
off values), disease spectrum and populations studied, variations in
NAAT protocols, and study quality across studies. When
significant heterogeneity is present, summary estimates from
meta-analyses are hard to interpret. We investigated heterogeneity
using subgroup (stratified) analysis and meta-regression analysis
[137]. In the subgroup analysis, we computed pooled DOR
estimates in various strata to determine if accuracy is higher in
specific subgroups.
Figure 1. Study selection process.
doi:10.1371/journal.pone.0001536.g001
Commercial Tests for TB
PLoS ONE | www.plosone.org 3 February 2008 | Issue 2 | e1536The meta-regression analysis is an extension of the SROC
model [135]. In this linear regression model, studies are the units
of analysis. The DOR is the outcome (dependent) variable. The
independent variables are the covariates that might be associated
with the variability in the DOR. Based on previous meta-analyses
[12–14], potentially relevant covariates for our meta-regression
model included: prospective or retrospective study direction,
recruitment method, blinded interpretation, type of test, specimen
type, reference standard, and data resolution. There were
insufficient numbers to compare categories of differing study
design, degree of verification, and smear status.
The meta-regression model generates relative diagnostic odds
ratios (RDOR) as the output [134,137]. An RDOR is a ratio of
two DORs. An RDOR of 1.0 indicates that a particular covariate
(e.g. blinded study design) does not affect the overall DOR. An
RDOR .1.0 indicates that studies with a particular characteristic
(e.g. those that employed a specific target sequence in the PCR)
have a higher DOR than studies without this characteristic. For a
RDOR ,1.0, the reverse holds.
RESULTS
The average sample size of the included studies was 715 (range 57–
7539). With the exception of one study, all of our studies were cross-
sectional. A majority (86%) of the studies were prospective in design.
A total of 45 (36%) studies used consecutive or random sampling,
while 29 (23%) studies recruited patients using some convenient
sampling. The convenient sample waschosen froma biggergroup of
patients or was selected from a screening program. All but two
studiesreportedcompleteverificationofNAATresultswiththesame
reference standard. Most of the studies (96%) collected both smear-
positive and smear-negative specimens, and 84% compared NAAT
results to culture as the reference standard. Ninety-five (76%) studies
tested respiratory specimens, while 30 (24%) studies only used
sputum specimens. We were able to analyze unresolved data (i.e. not
subjected to discrepant analyses) in 88 (70%) studies. Past evidence
has shown that investigators do not report all the study components
in their publications [6,138]. In our analysis, 103 (82%) studies did
not report blinding status, and 51 (41%) studies did not explicitly
report the method of patient recruitment. Table 2 gives the
characteristics of the studies in our meta-analysis.
The overall sensitivity and specificity estimates were 0.85 (range
0.36–1.00) and 0.97 (range 0.54–1.00), respectively. Figures 2 and
3 show the accuracy measures from all the studies in a forest plot.
Specificity appears to be more consistent than sensitivity. Thirteen
of 125 studies (10%) gave specificity estimates less than 90%. Most
of them included either patients on treatment or who had history
of prior disease. The overall LR+ was 32.74 (95% CI: 26.02,
41.22), and the overall LR- was 0.14 (95% CI: 0.12, 0.16). The
pooled DOR was 268.88 (95% CI: 212.07, 340.9). We used Chi-
square analysis to detect heterogeneity in the summary results. All
of them showed highly significant heterogeneity (p,.001). Thus,
pooled measures of the tests’ diagnostic accuracy are not
meaningful and do not adequately describe the data. Table 3
displays the accuracy measures and their corresponding statistics
for the Chi-square test of heterogeneity.
Heterogeneity is a common concern for diagnostic meta-
analyses. This variability may result from the threshold effect or
differences in test methods and study characteristics [135]. Figure 4
shows the SROC plot with studies weighted by their inverse
variance. The shoulder-like curve indicates that the threshold
effect exists in our meta-analysis. There is a trade-off between
sensitivity and specificity among the studies. Subgroup analysis is
also used to identify other sources of variability by stratifying data
into relatively more homogeneous strata [137]. Table 4 compares
the DOR estimates for the study characteristics. The heterogeneity
could be explained in some strata, but they consisted of small
numbers. We stratified by type of commercial kit since they have
standardized protocols. The variability in LR- did not persist for
the SDA test (Table 5). The SDA test amplifies IS6110, which is
usually present in high number of copies in MTB and may
increase sensitivity. However, only 6 studies evaluated the SDA
Table 2. Characteristics of NAAT Studies Included in the
Review (N=125)
......................................................................
Characteristic Frequency (%)
STUDY DIRECTION
Prospective 108 (86)
Retrospective 9 (7)
Both 8 (6)
STUDY DESIGN
Cross-Sectional 124 (99)
RECRUITMENT
Consecutive 43 (34)
Random 2 (2)
Convenient 24 (19)
Consecutive and Convenient 5 (4)
Not Reported 51 (41)
VERIFICATION
Complete 123 (98)
BLINDING
Both (double blind) 8 (6)
NAAT blinded to reference standard 7 (6)
Reference standard blinded to NAAT 5 (4)
None 2 (2)
Not Reported 103 (82)
NAAT
Amplicor 34 (27)
Cobas Amplicor 18 (14)
AMTD 31 (25)
E-AMTD 9 (7)
LCx 18 (14)
BD-ProbeTec 6 (5)
BD-ProbeTec-ET 9 (7)
SPECIMEN
Respiratory 95 (76)
Sputum 30 (24)
REFERENCE STANDARD
Culture 105 (84)
Clinical Data 3 (2)
Culture and Clinical Data 17 (14)
SMEAR STATUS
Both (positive and negative smears) 120 (96)
Negative 2 (2)
Not Reported 3 (2)
DATA
Resolved (after discrepant analysis) 37 (30)
Not Resolved (discrepant analysis not done) 88 (70)
doi:10.1371/journal.pone.0001536.t002
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
Commercial Tests for TB
PLoS ONE | www.plosone.org 4 February 2008 | Issue 2 | e1536test, and significant heterogeneity remained for the other
commercial NAATs.
A meta-regression analysis was performed to help explain the
variation even after subgroup analysis. Table 6 shows the RDOR
estimates from the meta-regression analysis using the Restricted
Maximum Likelihood (REML) method to measure between-study
variance. The threshold effect (S)=20.21 was significant
(p=0.01) in accordance with the SROC plot. The ‘‘S’’ coefficient
is a way to measure the effect of different thresholds on the DOR
Figure 2. Forest plot of sensitivity estimates and 95% CI. Point
estimates of sensitivity from each study are shown as solid circles. The
solid lines represent the 95% confidence intervals (CI). Circles are
proportional to study size. The pooled estimate is denoted by the
diamond at the bottom.
doi:10.1371/journal.pone.0001536.g002
Figure 3. Forest plot of specificity estimates and 95% CI. Point
estimates of specificity from each study are shown as solid circles. The
solid lines represent the 95% confidence intervals (CI). Circles are
proportional to study size. The pooled estimate is denoted by the
diamond at the bottom.
doi:10.1371/journal.pone.0001536.g003
Commercial Tests for TB
PLoS ONE | www.plosone.org 5 February 2008 | Issue 2 | e1536among studies, and the negative value indicates that the thresholds
increase specificity at the expense of sensitivity [16]. Thus, the
heterogeneity found in our meta-analysis could be explained in
part by the use of different cut-off values in the studies. In addition,
studies that evaluated respiratory specimens had almost a two-fold
increase in DOR compared to studies that used only sputum.
None of the other covariates in the model reached statistical
significance. Previous meta-analyses have shown that including
bronchial specimens gave higher accuracy estimates compared to
studies that only collected sputum [16,18].
DISCUSSION
Principal findings
Lack of rapid and accurate diagnostics for TB has been a major
concern for global TB control. NAATs were introduced as
promising novel tests for TB, and several commercial assays were
introduced into the market. However, their actual performance
has been less than optimal [12–18]. Since hundreds of studies have
been published on NAATs, there is now the opportunity to
perform meta-analyses and meta-regression to explore factors that
influence NAAT performance.
In this meta-analysis, we performed extensive literature searches
and identified a total of 125 separate studies from 105 articles that
reported NAAT results from respiratory specimens. The results
showed that sensitivity and specificity estimates for commercial
NAATs in respiratory specimens were highly variable, with sensitivity
lower and more inconsistent than specificity. Thus, summary
measures of diagnostic accuracy are not clinically meaningful. The
use of different cut-off values and the use of specimens other than
sputum could explain some of the observed heterogeneity.
Implications of the findings
The most notable advantage of commercial NAATs is their rapid
turn-around time, which may have important implications for
Table 3. Pooled Summary Estimates of 125 Commercial NAAT Studies (adding 0.5 to all cells of studies with 0 values)
..................................................................................................................................................
Accuracy Measure Accuracy Estimate (95% Confidence Interval) Chi
2 test of heterogeneity P value for heterogeneity
Sensitivity 0.85 (0.847, 0.86) 1121.69 ,.001
Specificity 0.968 (0.967, 0.969) 3748.64 ,.001
Positive Likelihood Ratio (LR+) 32.74 (26.01, 41.22) 3831.86 ,.001
Negative Likelihood Ratio (LR-) 0.14 (0.12, 0.16) 1495.00 ,.001
Diagnostic Odds Ratio (DOR) 268.88 (212.07, 340.9) 869.46 ,.001
doi:10.1371/journal.pone.0001536.t003
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Figure 4. SROC plot with best-fitting asymmetric curve. Each solid circle represents each study in the meta-analysis. The curve is the regression line
that summarizes the overall diagnostic accuracy. SROC=summary receiver operating characteristic; AUC=area under the curve; SE(AUC)=standard
error of AUC; Q*=an index defined by the point on the SROC curve where the sensitivity and specificity are equal, which is the point closest to the
top-left corner of the ROC space; SE(Q*)=standard error of Q* index.
doi:10.1371/journal.pone.0001536.g004
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impacted by a trade-off between sensitivity and specificity—
specificity appears maximized at the cost of sensitivity. Reasons to
account for their low sensitivity include low concentration of bacilli
(i.e. paucibacillary specimens), such as smear-negative sputum
specimens, or the presence of inhibitory substances [139]. We did
not find high rates of inhibition in the studies reviewed (range 1%–
7.5%). In addition, the small volumes of specimen (template) used
in each commercial test may offer additional explanations. A
recent meta-analysis on NAATs for TB lymphadenitis found that
studies which used volumes of template .20 ml were more
accurate than studies that used lesser template volumes [17].
Furthermore, study results may be influenced by the reference
standard used to compare test results. It is well known that culture
is not 100% sensitive and can give false-negative results. The lack
of a diagnostic gold standard remains one of the biggest obstacles
for evaluating new diagnostics, especially in HIV-infected persons
and in paucibacillary disease (e.g. extrapulmonary TB and
pediatric disease). The true accuracy of commercial NAATs may
actually be higher than reported when using an imperfect
reference standard [140].
Our results show a high degree of variability in accuracy across
studies. The increased power of a meta-analysis can determine a
test’s overall diagnostic ability, but a summary measure is
misleading in the presence of significant heterogeneity. In previous
meta-analyses [12–14], subgroup analyses did not fully explain the
variability found in NAAT results across studies. Even when
stratifying by commercial test, our results remained heterogeneous.
Other setting-specific factors, such as background TB prevalence
rates or laboratory experience, could help account for this variation.
Aside from the threshold effect, meta-regression analysis found that
studies which collected several types of respiratory specimens were
associated with higher diagnostic accuracy, possibly since the
induction of aspirates yields a higher recovery of bacteria. Our
findings agree with previous meta-analyses that suggest commercial
NAATs cannot replace culture and microscopy but should be
interpreted along with conventional tests and clinical data for
diagnosing TB[12,13,15].NAATs arealsonotusefulfor monitoring
treatmentprogresssincetheycandetectnon-viablebacteriaand give
false-positive results [141]. However, they can distinguish M.
tuberculosis from NTM [9]. This may be helpful in high-NTM
populations, such as HIV/AIDS patients.
Limitations of NAAT studies
Systematic reviews and meta-analyses are critical for evidence-based
clinical practice [131,142]. However, they are only as good as the
quality of the studies that they include. There is growing concern
that primary research on TB diagnostics are not methodologically
rigorous [143,144]. In a review of 12 recent meta-analyses of various
TB tests, studies were plagued by limitations such as lack of blinding,
use of a case-control design, and lack of random or consecutive
patient sampling methodology [6]. One review of 31 meta-analyses
on several diseases found higher accuracy measures associated with
studies that used non-consecutive sampling methods [138]. In our
meta-regression, the use of some convenience sampling gave a DOR
that was 1.5-fold higher than the DOR for studies that used random
or consecutive sampling. This finding was almost significant
(p=0.15). In addition, 41% of our studies did not report how their
patients were recruited. Thus, besides poor methodological quality,
poor reporting of study components is another problem [6]. In our
meta-analysis, 82% of the studies did not report blinding status. Not
blinding investigators to reference standard results when interpreting
the NAAT test has been shown to overestimate the DOR
[13,16,145]. Another limitation of existing NAAT studies is lack of
data on whether NAATs actually have an impact on patient
outcomes and how much value NAATs contribute, over and above
the information already obtained by conventional testing. Most
studies only provided information on sensitivity and specificity.
Table 4. Diagnostic Odds Ratio (DOR) Estimates from
Subgroup Analysis
......................................................................
Study Characteristic
(n) DOR
Chi
2 test of
heterogeneity
P value for
heterogeneity
DIRECTION
Prospective (108) 255.63 (199.23, 328.01) 678.67 ,.001
Retrospective (9) 315.65 (99.68, 999.57) 150.21 ,.001
Both (8) 371.42 (161.83, 852.49) 31.40 ,.001
STUDY DESIGN
Cross Sectional
(124)
269.56 (212.30, 342.26) 869.08 ,.001
RECRUITMENT
Consecutive (43) 220.90 (154.41, 316.00) 180.24 ,.001
Convenient (24) 347.98 (225.63, 536.67) 91.71 ,.001
Both (5) 298.50 (90.72, 982.18) 40.54 ,.001
Random (2) 278.72 (3.12, 24901.4) 9.73 0.002
Not Reported (51) 284.91 (184.02, 441.13) 529.38 ,.001
VERIFICATION
Complete (123) 264.79 (208.66, 336) 863.88 ,.001
BLINDING
Both (8) 163.93 (69.91, 384.42) 25.49 0.001
NAAT blinded (7) 446.86 (45.83, 4357.6) 106.41 ,.001
Reference test
blinded (5)
136.79 (76.13, 245.75) 4.55 0.337
Not Blinded (2) 84.26 (5.99, 1184.50) 5.39 0.020
Not Reported (103) 286.86 (223.72, 367.82) 681.83 ,.001
NAAT
Amplicor (34) 174.92 (120.77, 253.35) 198.52 ,.001
Cobas Amplicor (18) 399.07 (238.32, 668.25) 83.93 ,.001
AMTD (31) 298.05 (155.13, 572.62) 332.38 ,.001
E-AMTD (9) 822.72 (194.22, 3485.1) 55.72 ,.001
LCx (18) 215.60 (145.98, 318.44) 40.41 0.001
BD-ProbeTec (6) 424.45 (174.15, 1034.5) 10.96 0.052
BD-ProbeTec-ET (9) 266.86 (110.04, 647.19) 46.93 ,.001
SPECIMEN
Respiratory (95) 319.21 (247.88, 411.07) 546.49 ,.001
Sputum (30) 138.91 (86.26, 223.70) 197.27 ,.001
REFERENCE STANDARD
Culture (105) 271.30 (211.67, 347.73) 688.15 ,.001
Clinical Data (3) 70.30 (4.04, 1224.60) 40.06 ,.001
Culture and Clinical
(17)
300.84 (163.1, 554.92) 70.57 ,.001
SMEAR STATUS
Both (120) 270.79 (212.77, 344.63)
61.79 (17.83, 214.14)
837.09 ,.001
Negative (2) 828.06 (317.8, 2157.6) 3.14 0.076
Not Reported (3) 0.04 0.982
DATA
Resolved (37) 254.01 (177.34, 363.81) 200.87 ,.001
Not Resolved (88) 278.33 (203.79, 380.13) 668.45 ,.001
doi:10.1371/journal.pone.0001536.t004
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PLoS ONE | www.plosone.org 7 February 2008 | Issue 2 | e1536Strengths and limitations of the systematic review
Our systematic review had several strengths. First, we used a
comprehensive search strategy with various overlapping approach-
es. This enabled us to retrieve a large number of studies.
Moreover, two reviewers independently completed screening,
study selection, and data extraction. Finally, we analyzed data
within specific subgroups to lessen the effect of heterogeneity and
used meta-regression to identify factors associated with higher
accuracy. Our review had limitations as well. Despite searching
several sources, it is possible that we may have missed some eligible
studies. Further, we could only extract data from English language
studies, and this could have introduced bias in our results. Lastly,
despite using subgroup analysis and meta-regression methods,
considerable heterogeneity remained unexplained.
Even if sensitivity were to be improved, an important issue that
will remain is the implementation of these new tools in developing
countries. Commercial kits, whose prices range from US$25–50
per test, are popular in the US and other developed countries
[9,11]. The US Center for Disease Control and Prevention (CDC)
has reported that commercial NAATs are used mostly in hospitals,
health departments, and independent laboratories in the US
[146]. However, many developing countries still use in-house PCR
assays, which only cost about $15 per test [147]. Ironically, the
poorest countries are often the ones burdened by the highest
number of cases and therefore unlikely to benefit from expensive
technologies. Realizing this, agencies such as the Foundation for
Innovative New Diagnostics (FIND), the WHO, and the Stop TB
Working Group for New Diagnostics have launched initiatives to
make technologies for detecting TB and other neglected diseases
affordable and accessible for developing countries [148].
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